Artelo Biosciences Expands ART27.13 Into GLP-1 Therapy Market For Muscle Preservation, Backed by Trials And New Patent

Artelo Biosciences, Inc. has announced a strategic expansion opportunity for its investigational candidate ART27.13, focusing on muscle preservation in patients undergoing GLP-1 receptor agonist therapy. This move reflects the company’s effort to position the drug as a potential companion treatment in a rapidly growing therapeutic category.

The initiative is backed by multiple developments, including findings from the CAReS trial showing improvements in lean body mass and physical activity among cancer patients, as well as preclinical research led by Richard Porter at Trinity College Dublin. Additional support comes from peer-reviewed studies highlighting ART27.13’s differentiated pharmacology, alongside a newly filed provisional patent covering cannabinoid receptor agonism to address muscle loss linked to GLP-1 therapies. The company has also initiated a non-clinical study to further evaluate this potential.

“GLP-1 medicines are reshaping the treatment landscape for obesity and metabolic disease, yet preservation of muscle and lean body mass remains a critical issue for patients, physicians, and the industry,” said Dr. Andrew Yates, Senior Vice President and Chief Scientific Officer of Artelo. “We believe ART27.13 may represent a differentiated approach as a potential companion therapy in this setting. Based upon the results and analysis published in a recent independent research study, “Kinetic multiplex assay to assess biased signaling of clinical GPCR agonists”, wherein the authors described ART27.13 as a superagonist, we consider our GPCR drug candidate to have one of the most compelling pharmacologic profiles among the 17 clinically studied CB2 agonists. With new non-clinical research commencing and the recent filing of a patent application covering the use of CB2 agonists with GLP-1 drugs, we are aiming to build a scientific and strategic foundation with ART27.13 in an area of potentially significant commercial relevance.”

These developments come amid growing use of GLP-1-based treatments, for which research suggests a significant portion of weight loss may come from lean muscle mass, underscoring an unmet clinical need. ART27.13 is being explored to help mitigate this issue, positioning it within a high-growth segment of the biopharma market projected to expand substantially by 2030.

“Our strategy is to advance ART27.13 where the biology, clinical need and commercial opportunity intersect,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo. “The rapid adoption of GLP-1 therapies has created a large and increasingly visible need for solutions that may help address treatment-associated muscle loss. We believe Artelo is moving quickly to establish an early prominent role in what could become an important adjunct category within the GLP-1 treatment landscape.”

Separately, Artelo recently disclosed plans for a fully funded third-party clinical study expected to begin in Q2 2026 to evaluate ART27.13 in glaucoma patients, underscoring the compound’s broader therapeutic potential across multiple indications.